Table 2.
Prevalence of positive MF, Og4C3, IgG4, and IgG responses to Bm14 and Bm33 at time points A, B, and C for all treatment groups, Haiti*
| Observation | % Positive (no. positive/no. tested) in each treatment group | |||
|---|---|---|---|---|
| Placebo | ALB | DEC | DEC/ALB | |
| Pretreatment (time point A) | ||||
| Bm14 IgG | 73 (30/41) | 86 (31/36) | 72 (31/43) | 89 (25/28) |
| Bm33 IgG | 88 (36/41) | 94 (34/36) | 95 (41/43) | 93 (26/28) |
| Bm14 IgG4 | 82 (18/22) | 79 (19/24) | 67 (16/24) | 88 (22/25) |
| Bm33 IgG4 | 59 (13/22) | 58 (14/24) | 67 (16/24) | 60 (15/25) |
| Og4C3 | 44 (18/41) | 36 (13/36) | 28 (12/43) | 32 (9/28) |
| MF | 22 (10/37) | 12 (6/34) | 15 (6/39) | 4 (1/24) |
| Three months post-treatment (time point B) | ||||
| Bm14 IgG | 76 (31/41) | 83 (30/36) | 67 (29/43) | 86 (24/28) |
| Bm33 IgG | 88 (36/41) | 100 (36/36) | 88 (38/43) | 93 (26/28) |
| Bm14 IgG4 | 82 (18/22) | 79 (19/24) | 58 (14/24) | 84 (21/25) |
| Bm33 IgG4 | 59 (13/22) | 54 (13/24) | 46 (11/24)† | 36 (9/25) |
| Og4C3‡ | ||||
| MF | 24 (7/29) | 23 (5/22) | 14 (4/28) | 0 (0/19) |
| Six months post-treatment (time point C) | ||||
| Bm14/IgG | 78 (32/41) | 89 (32/36) | 65 (28/43) | 86 (24/28) |
| Bm33/IgG | 93 (38/41) | 100 (36/36) | 86 (37/41) | 89 (25/28) |
| Bm14/IgG4 | 82 (18/22) | 83 (20/24) | 54 (13/24) | 76 (19/25) |
| Bm33/IgG4 | 64 (14/22) | 54 (13/24) | 29 (7/24)† | 36 (9/25) |
| Og4C3 | 41 (17/41) | 33 (12/36) | 23 (10/43) | 32 (9/28) |
| MF | 24 (6/25) | 17 (4/24) | 14 (4/28) | 0 (0/17) |
*
MF = microfilaremia; ALB = albendazole; DEC = diethylcarbamazine.
†
Prevalence significantly lower (P < 0.043) than time point A (by z test).
‡
Not tested.